UniQure Gene Therapy Trial Failed Primary Endpoint
The company's Huntington's disease treatment failed to reach a statistically significant slowing of the condition.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you generally trust pharmaceutical companies to successfully develop effective treatments for rare diseases?
UniQure shares plummeted 55% in premarket trading after its experimental gene therapy, AMT-130, failed to meet its primary endpoint. The drug did not show a statistically significant slowing of disease progression in the study.
Why it matters
Huntington's disease is an inherited brain disorder that causes cognitive, behavioral, and movement decline, yet no approved drugs currently exist to slow the disease's progression. This trial failure leaves a significant gap in treatment options for the inherited condition.
The study utilized a sample of 12 high-dose patients over a 48-month analysis period. While the treatment showed a 44% slowing of disease progression compared to an external control, it failed to reach the threshold for statistical significance.
The players
UniQure
A biotechnology company focused on developing gene therapies for severe genetic diseases.
The details
The gene therapy AMT-130 was designed to treat Huntington's disease, an inherited brain disorder that leads to severe movement, behavioral, and cognitive decline. Because no other therapies are currently approved to slow the progression of the disease, the failure of this study represents a major setback for the company and the patient population.
Timeline
September 29, 2026: UniQure reported the trial failure and shares plummeted.
48 months: The total duration for the study analysis window.
The Tech Race
This trial result significantly impacts the trajectory of gene therapy research for neurodegenerative disorders, where the industry has long sought a breakthrough treatment. It follows a pattern set by previous efforts in gene therapy development for Huntington's disease, where therapeutic outcomes have proven difficult to achieve in clinical trials.
The clinical failure means that patients living with Huntington's disease will not gain access to AMT-130 as a treatment option in the near term. This result underscores the continued absence of any pharmacological intervention capable of slowing the progression of the neurodegenerative condition.
The takeaway
The lack of successful clinical outcomes for Huntington's disease underscores the immense difficulty of treating complex, inherited brain disorders. Patients and families should continue to look toward clinical trial registries for upcoming research opportunities into new therapeutic candidates.
Further reading
For more on the current state of genetic medicine, visit our Biotech section.
Live Poll
Do you generally trust pharmaceutical companies to successfully develop effective treatments for rare diseases?
